Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Sienna Diagnostics Inks Singapore Distribution Deal for Bladder Cancer Test

Sienna Diagnostics Inks Singapore Distribution Deal for Bladder Cancer Test

Feb 04, 2019
|
staff reporter

NEW YORK (360Dx) — Sienna Cancer Diagnostics said today that it has signed an agreement making Mediwell a non-exclusive distributor of its bladder cancer diagnostic in Singapore.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Cancer

  1. Amid Interest Generated by Coronavirus Testing, IPO Window Open for Dx Firms in 2020

    Premium

  2. Payor Policy Study Reveals Progress, Challenges in Liquid Biopsy Reimbursement

  3. Thermo Fisher Scientific, Chugai Pharmaceutical Sign Companion Diagnostic Agreement for NSCLC

  4. Guardant Health to Develop Liquid Biopsy Companion Diagnostic for Janssen NSCLC Therapy

  5. NCI Researchers Leverage Machine Learning for Accurate, Broader-Scale Cervical Cancer Screening

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.